<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2016-07-11 16:59:22Medicine Biotechnology PEGylation Pharmacokinetics Pegloticase Savient pharmaceuticals Biology Health Urate oxidase Gout Uric acid Pharmaceutical industry in China |
Add to Reading List |
Microsoft Word - Savient Phase 3 Dosing press releasedoc | ORIGINAL ARTICLE Clinical Implications of Molecular PEGylation on Therapeutic Proteins Nandhakumar Sathyamoorthy, Dhanaraju Dasaratha Magharla Department of Pharmaceutics, GIET School of Pharmacy, Rajahmundry, Andhra PrDocID: 1uHNe - View Document |
 | Conjugates prepared with aggregate-free proteins - European Patent Office - EPB1 Conjugates prepared with aggregate-free proteins - European Patent Office - EPB1DocID: 1rrGr - View Document |
 | Peg-urate oxidase conjugates and use thereof - European Patent Office - EPB1 Peg-urate oxidase conjugates and use thereof - European Patent Office - EPB1DocID: 1rrm1 - View Document |
 | Microsoft Word - Savient Press Release ACRdocDocID: 1rrcY - View Document |
| Microsoft Word - Savient Phase 3 Dosing press releasedocDocID: 1ri7E - View Document |